Poseida in the News

Explore recent media coverage of Poseida and find out how we are creating the next wave of cell and gene therapies with the capacity to cure.

The Top Line

Fierce Biotech | November 11, 2022

Devon J. Shedlock, PhD, on Shifting from Autologous to Allogeneic Therapies

CGT Live | October 14, 2022

Allogeneic Cell Therapy Results: Delving A Little Deeper

Cell & Gene | October 3, 2022

CRISPR-Cas9 Alternatives: Cutting through the Boundaries of Gene Editing

Genetic Engineering & Biotechnology News | August 24, 2022

CAR-T Cell Therapies for Hematologic Malignancies the Focus of New Poseida, Roche Collaboration

CGT Live | August 8, 2022

Roche Dives Deeper into Off-The-Shelf Cell Therapies in Poseida Partnership

Gene Online | August 4, 2022

Roche wades deeper into the allogeneic CAR-T field, reserving billions for its next early-stage partner

Endpoints News | August 3, 2022

Roche digs into off-the-shelf cell therapy with Poseida deal

BioPharma Dive | August 3, 2022

Novel Cell and Gene Therapies
Mark Gergen, CEO, Poseida Therapeutics, Inc.

Biotech 2050 Podcast | July 13, 2022

Moving on from AAV with Poseida Therapeutics’ CEO, Mark Gergen

Cell & Gene: The Podcast | June 22, 2022

Spotlight on Poseida’s CAR-T Strategy

Celltelligence | June 22, 2022

Providing new hope for rare disease using non-viral gene therapy

Drug Target Review | June 20, 2022

The “Renaissance” Approach To Cell & Gene Therapy Manufacturing

Cell & Gene Collaborative | June 13, 2022

Targeting Solid Tumors with Cell Therapies

Cell & Gene | March 29, 2022

Building the Next-Generation of Cell and Gene Therapies

The Bio Report Podcast | March 23, 2022

Interview with Poseida CEO Mark Gergen

Tacos and Tech Podcast | March 8, 2022

Poseida taps former Novartis VP as president of gene therapy

Fierce Biotech | February 22, 2022

Memory T Cell CAR T Therapy Showcases Anti-Tumor Activity
in Resistant Prostate Cancer

CGT Live | February 17, 2022